One Pager as on February 29, 2024
Selection of the next potential winners through the GCMV process# | |
High conviction focused portfolio with strong risk management processes | |
Potential to generate relatively better risk adjusted returns | |
# GCMV is an internal process framework to optimize stock selection based on growth, cashflow, management and valuation
Sector | MMFF | NSE 500 Index TRI |
Financial Services | 27.27% | 28.20% |
Oil Gas & Consumable Fuels | 16.25% | 9.58% |
Information Technology | 10.16% | 10.54% |
Fast Moving Consumer Goods | 7.08% | 7.29% |
Automobile And Auto Components | 5.41% | 6.79% |
Data as on February 29, 2024
Security | % to Net Assets |
ICICI Bank Limited | 8.44% |
Reliance Industries Limited | 8.36% |
State Bank of India | 6.44% |
Infosys Limited | 5.41% |
Grasim Industries Limited | 4.80% |
Kotak Mahindra Bank Limited | 4.01% |
Hindustan Unilever Limited | 3.60% |
Indus Towers Limited | 3.50% |
Sun Pharmaceutical Industries Limited | 3.36% |
Coal India Limited | 3.33% |
Total | 51.25% |
Fresh Additions | Complete Exits |
Security | Security |
GAIL (India) Limited | Gujarat State Fertilizers & Chemicals |
IndusInd Bank Limited | Larsen & Toubro Limited |
Union Bank of India | NHPC Limited |
- | Piramal Enterprises Limited |
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant portfolio
changes during the month and should not be construed as recommendation to buy/sell/ hold. The fund manager
may or may not choose to hold these companies/stocks, from time to time. Investors are requested to consult
their financial, tax and other advisors before taking any investment decision(s). Data as on February 29, 2024
Turnover Ratio (Last 1 year) | 0.80 |
Standard Deviation | 12.77% |
Beta | 0.89 |
Sharpe Ratio# | 1.30 |
Jenson's Alpha | 0.4717 |
#Risk-free rate assumed to be 6.80% (MIBOR as on 29-02-24) - Source:www.mmda.org
Note: As per AMFI guidelines for factsheet, the ratios are calculated based on month rolling returns
for last 3 years. Data as on February 29, 2024
^Benchmark ^^Additional Benchmark. Inception/Allotment date: 17-Nov-20.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of
Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. *Based on standard investment of Rs. 10,000
made at the beginning of the relevant period. Ms. Fatema Pacha is managing this scheme since December 21, 2020
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 17-Nov-20.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal
amounts invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment
internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
The performance details provided above are
of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Krishna Sanghavi manages 2 scheme and
Ms. Fatema Pacha manages 8 schemes of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
Performance as on February 29, 2024
This product is suitable for investors who are seeking*:
• Long term capital appreciation;
• Investment in equity and equity
related instruments in concentrated
portfolio of maximum 30 stocks
across market capitalziation.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.